SpectralX — Interactive Platform Demo

Step 1 — Variant position histogram

—

Step 2 — Power spectral density (log–log)

FFT slope → spectral exponent β

The separation is real. Move the line and see.

Sixty-five FDA-validated drug targets plotted by spectral exponent (β) and fractal dimension (FD). Drag the threshold line — watch classification accuracy update against the ground-truth modality of each approved drug.

Small molecule (n=28) Gene therapy (n=25) Synthetic lethality (n=12)

FD threshold

FD = 0.736

73.8%

Binary classification accuracy

Default FD = 0.736 is the patent-disclosed optimum, separating small-molecule targets (below) from gene-therapy and synthetic-lethality targets (above).

SARS-CoV-2 Spike — the call SpectralX would have made before Omicron existed.

Fractal Hotspot Score (FHS) computed from pre-Omicron genomic surveillance data. High FHS = structurally constrained, escape-resistant. Low FHS = under diversifying selection, escape-prone. Click an antibody to see its epitope window, the FHS the platform would have reported, and the real-world Omicron outcome.

ρ = −0.510

Spearman correlation between pre-Omicron FHS and measured Omicron antibody escape across 392,456 escape measurements · 1,535 monoclonal antibodies (Bloom Laboratory dataset). The platform's call is independent, prospective, and computed from public sequence data only.

Your portfolio

Therapeutic area

Programs in flight

Avg cost per Phase II/III modality-mismatch ($M)

Industry baseline mismatch rate

5%15%30%

Mismatches caught by SpectralX (modeled)

20%55%80%

Modeled annual avoided loss

$0M

avoided wrong-modality spend per year

Programs at risk

Caught pre-IND

0×

ROI on platform license

Anchored to Deloitte 2023: $145.5B top-20 biopharma R&D spend, 4.1% ROI, $2.3B avg cost per drug, 6.7% Phase I approval likelihood. Catch rate is a modeled lever — actual performance depends on portfolio composition. ROI assumes a representative platform license cost of $2M/year.